title: JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Barosi
authors.affiliation: Biometry and Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Klersy
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Villani
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Bonetti
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Catarsi
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Poletto
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Campanelli
authors.affiliation: Hematology, Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Impera
authors.affiliation: Department of Cellular Biotechnology and Hematology, University of Rome, La Sapienza, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Latagliata
authors.affiliation: Immunohematology and Transfusion Service, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Viarengo
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Carolei
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Massa
authors.affiliation: Dipartimento Oncologico 'La Maddalena', UO di Oncologia e Trapianto di Midollo, Palermo, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Musso
authors.affiliation: Dipartimento Oncologico 'La Maddalena', UO di Oncologia e Trapianto di Midollo, Palermo, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Crescimanno
authors.affiliation: Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.affiliation: Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Rosti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D016016:Proportional Hazards Models; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D013163:Splenomegaly / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2